Categories
Change Password!
Reset Password!
Degenerative spondylolisthesis (DS) is a prevalent age-related spinal disorder often managed with single-level lumbar fusion surgery.
Older adults undergoing lumbar fusion for degenerative spondylolisthesis show higher 90-day readmission risk driven by age, comorbidities (especially VTE and myocardial infarction), postoperative complications, and longer hospital stay.
Degenerative spondylolisthesis (DS) is a prevalent age-related spinal disorder often managed with single-level lumbar fusion surgery. However, older adults (≥60 years) face a higher likelihood of postoperative complications and hospital readmission. This study sought to identify key risk factors for 90-day readmission after lumbar fusion to improve patient outcomes and decrease healthcare burden.
Investigators analyzed data from the National Readmission Database (2016–2020), including 32,894 patients aged ≥60 years who underwent single-level lumbar fusion for DS. Using multivariable logistic regression analysis, the independent predictors of 90-day hospital readmission was checked.
In this retrospective cohort study, the cohort had a mean age of 70 years, with 65% female patients. Multiple clinical and healthcare-related factors were associated with increased readmission risk, as depicted in Table 1:
Age-stratified analysis (≥70 years) illustrated distinct risk patterns, emphasizing the importance of age-specific perioperative risk assessment and management.
Significant predictors of 90-day readmission after lumbar fusion in DS include age, comorbidities, perioperative complications, insurance status, and hospital length of stay. Adopting personalized perioperative strategies and optimized postoperative care pathways may help reduce readmission rates, enhance recovery, and minimize healthcare costs in elderly patients.
Experimental Gerontology
Risk factors for 90-day readmission after single-level lumbar fusion for degenerative spondylolisthesis in older adults: A National Readmission Database Analysis, 2016–2020
Yu-Chiang Yeh
Comments (0)